Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients

Basit Öğe Kaydı
dc.contributor.authorCoskun, U.
dc.contributor.authorGunel, N.
dc.contributor.authorSancak, B.
dc.contributor.authorOnuk, E.
dc.contributor.authorBayram, M.
dc.contributor.authorCihan, A.
dc.date.accessioned2020-06-25T17:40:03Z
dc.date.available2020-06-25T17:40:03Z
dc.date.issued2004
dc.departmentKırıkkale Üniversitesi
dc.description.abstractVascular endothelial growth factor (VEGF) is a multi-functional cytokine that has been suggested to be a major angiogenic factor in breast cancer. Nitric oxide (NO) is a potent biological molecule that partipicates in the multi-step process of carcinogenesis. Interleukin (IL)-18 has been shown to have potent anti-tumour effects. In this study, we investigated the effect of tamoxifen therapy on serum VEGF, NO and IL-18 activity in breast cancer patients. Serum levels of VEGF, nitrate + nitrite and IL-18 were measured in 34 postmenopausal breast cancer patients before and 3 months after the tamoxifen therapy. Both serum VEGF and IL-18 levels decreased after tamoxifen therapy (P = 0.051, P < 0.05, respectively). Serum VEGF levels increased in patients with endometrial thickness, while patients without endometrial thickness had a significant reduction in serum VEGF levels after therapy (P < 0.05). Serum nitrate + nitrite levels increased after the therapy, but this was not statistically significant (P > 0.05). A decrease in serum VEGF levels with tamoxifen therapy may be a reflection of reduced angiogenic activity in patients without endometrial thickness. The negative effect of tamoxifen therapy on IL-18, which is known to have a potent antitumour activity, may be related to the decreased tumour growth by induction of NO and reduction of VEGF activity as a feedback mechanism.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1111/j.1365-2249.2004.02579.x
dc.identifier.endpage551en_US
dc.identifier.issn0009-9104
dc.identifier.issn1365-2249
dc.identifier.issue3en_US
dc.identifier.pmid15320904
dc.identifier.scopus2-s2.0-4344659570
dc.identifier.scopusqualityQ2
dc.identifier.startpage546en_US
dc.identifier.urihttps://doi.org/10.1111/j.1365-2249.2004.02579.x
dc.identifier.urihttps://hdl.handle.net/20.500.12587/3238
dc.identifier.volume137en_US
dc.identifier.wosWOS:000223469800012
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWileyen_US
dc.relation.ispartofClinical And Experimental Immunology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectangiogenesisen_US
dc.subjectapoptosisen_US
dc.subjectbreast canceren_US
dc.subjecthormone therapyen_US
dc.subjectnitrateen_US
dc.subjectnitriteen_US
dc.titleEffect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patientsen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients.pdf
Boyut:
125.51 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu